Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: Analysis by a PBPK model

Pharmaceutical Research

Volumn 28, Issue 3, 2011, Pages 531-539

  Gérard, Cécile ^a,b   Bleyzac, Nathalie ^b,c   Girard, Pascal ^a,b   Freyer, Gilles ^a,b   Bertrand, Yves ^b,c   Tod, Michel ^a,b,d  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c Institut d'Hematologie et d'Oncologie Pediatrique   (France)

^d CROIX ROUSSE HOSPITAL   (France)

Author keywords

bone marrow transplantation; cyclosporin; GVHD; PBPK modelling

Indexed keywords

CYCLOSPORIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW TRANSPLANTATION; BONE TISSUE; CHILD; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG INTERMITTENT THERAPY; DRUG TISSUE LEVEL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; INTESTINE; LOGISTIC REGRESSION ANALYSIS; LYMPHOID ORGAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; STATISTICAL ANALYSIS; STATISTICAL MODEL;

ADOLESCENT; AREA UNDER CURVE; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; MALE; MODELS, BIOLOGICAL; RETROSPECTIVE STUDIES; TISSUE DISTRIBUTION;

EID: 79952484129     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0299-z     Document Type: Article

References (28)

1. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009;373:1550-61.
2. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411:385-9. (Pubitemid 32467049)
3. Bowers LD. Therapeutic monitoring for cyclosporine: difficulties in establishing a therapeutic window. Clin Biochem. 1991;24:81-7.
4. Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH, et al. Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant. 2003;32:777-84. (Pubitemid 38455941)
5. Byrne JL, Stainer C, Hyde H, Miflin G, Haynes AP, Bessell EM, et al. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis. Bone Marrow Transplant. 1998;22:541-5. (Pubitemid 28445752)
6. Carlens S, Aschan J, Remberger M, Dilber M, Ringden O. Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia. Bone Marrow Transplant. 1999;24:629-35. (Pubitemid 29446137)
7. Cahn JY, Klein JP, Lee SJ, Milpied N, Blaise D, Antin JH, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005;106:1495-500. (Pubitemid 41129621)
8. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant. 1997;19:759-64.
9. Gerard C, Bleyzac N, Girard P, Freyer G, Bertrand Y, Tod M. Influence of dosing schedule on organ exposure to cyclosporin in pediatric hematopoietic stem cell transplantation: analysis with a PBPK-PD model. Pharm Res. 2010. doi:10.1007/s11095-010-0252-1.
10. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 postrenal transplantation and incidence of rejection in the first month. Ther Drug Monit. 2002;24:479-86. (Pubitemid 34857899)
11. Pescovitzand MD, Barbeito R. Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant. 2002;16:378-82.
12. Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, et al. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transpl Int. 2005;18:116-24. (Pubitemid 41742955)
13. Li J, Dahmen U, Beckebaum S, Cicinnati V, Valentin-Gamazo C, Frilling A, et al. Target range maximum of cyclosporine blood concentration two hours post dose in stable liver transplant patients. Eur J Med Res. 2006;11:139-45.
14. Rodrigo E, Ruiz JC, Angeles de Cos M, Ruiz J, Gago M, Pinera C, et al. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation. Transplant Proc. 2009;41:2328-31.
15. Troncoso P, Ortiz AM, Jara A, Vilches S. Abbreviated AUC monitoring of cyclosporine more adequately identified patients at risk for acute rejection during induction of immunosuppressive therapy after kidney transplantation than recommended C2 concentration values. Transplant Proc. 2009;41:127-30.
16. Barkholt L, Remberger M, Bodegard H, Ringden O, Bottiger Y. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2007;40:683-9. (Pubitemid 47456483)
17. Punnett A, Sung L, Price V, Das P, Diezi M, Doyle J, et al. Achievement of target cyclosporine concentrations as a predictor of severe acute graft versus host disease in children undergoing hematopoietic stem cell transplantation and receiving cyclosporine and methotrexate prophylaxis. Ther Drug Monit. 2007;29:750-7. (Pubitemid 350190851)
18. Sibbald C, Seto W, Taylor T, Saunders EF, Doyle J, Dupuis LL. Determination of area under the whole blood concentration versus time curve after first intravenous cyclosporine dose in children undergoing hematopoietic stem cell transplant: limited sampling strategies. Ther Drug Monit. 2008;30:434-8.
19. Martin P, Bleyzac N, Souillet G, Galambrun C, Bertrand Y, Maire PH, et al. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant. 2003;32:881-7. (Pubitemid 37369265)
20. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18:295-304.
21. Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827-38.
22. Michallet M, Dhedin N, Michallet AS. Allogeneic hematopoietic stem-cell transplantation for hematological malignancies. Bull Cancer. 2001;88:908-26. (Pubitemid 32964306)
23. Meille C, Iliadis A, Barbolosi D, Frances N, Freyer G. An interface model for dosage adjustment connects hematotoxicity to pharmacokinetics. J Pharmacokinet Pharmacodyn. 2008;35:619-33.
24. Neudorf S, Sanders J, Kobrinsky N, Alonzo TA, Buxton AB, Gold S, et al. Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood. 2004;103:3655-61. (Pubitemid 38596278)
25. Miller KB, Schenkein DP, Comenzo R, Erban JK, Fogaren T, Hirsch CA, et al. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol. 1994;68:15-20. (Pubitemid 24052470)
26. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graftversus-host disease after marrow transplantation from unrelated donors. Blood. 2000;96:2062-8.
27. Ogawa N, Kanda Y, MatsubaraM, Asano Y, Nakagawa M, Sakata-Yanagimoto M, et al. Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplant. 2004;33:549-52. (Pubitemid 38425787)
28. Hendriks MP, Blijlevens NM, Schattenberg AV, Burger DM, Donnelly JP. Cyclosporine short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2006;38:521-5. (Pubitemid 44445358)